2018 / 05

Next Paper
DOI: 10.24075/brsmu.2018.064

ORIGINAL RESEARCH

Testing of monoclonal antibodies against the T-cell receptor associated with ankylosing spondylitis

Israelson MA1,3, Stepanov AV2, Staroverov DB1,3, Shagina IA1, Misorin AK4, Evstratieva AV4, Merzlyak EM1,3, Bogdanova EA1, Britanova OV3, Lukyanov SA1
About authors

1 Department of Molecular Technologies, Institute of Translational Medicine,
Pirogov Russian National Research Medical University, Moscow

2 Department of Peptide and Protein Technologies, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow

3 Department of Adaptive Immunity Genomics, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow

4 BIOCAD, Saint-Petersburg

Correspondence should be addressed: Olga V. Britanova
Miklouho-Maclay 16/10, Moscow, 117997; moc.liamg@natirblo

About paper

Funding: this work was supported by the Ministry of Science and Education of the Russian Federation, Project ID RFMEFI60716X0158.

Received: 2018-09-13 Accepted: 2018-10-11 Published online: 2018-12-05
|
  1. Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled shortterm trial. Ann Rheum Dis. 2014; 73 (1): 243–6.
  2. Rihl M, Baerlecken N, Wiese B, Schmidt RE, Zeidler H. Intravenous glucocorticoid pulse therapy in active, NSAID refractory axial ankylosing spondylitis: a retrospective analysis spanning 12 months. J Arthritis. 2018; (7): 1. DOI: 10.4172/2167- 7921.1000266
  3. Fujita T, Kutsumi H, Sanuki T, Hayakumo T, Azuma T. Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries. J. Gastroenterol. 2013; (48): 559–73. DOI: 10.1007/s00535-013- 0771-8
  4. Xu T, Ying T, Wang L, Zhang XD, Wang Y, Kang L et al. A nativelike bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factoralpha and interleukin-17A. Oncotarget. 2017; 8 (47): 81860–72. DOI: 10.18632/oncotarget.19899.
  5. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011; (70): 905–8.
  6. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al.Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002; 359 (9313): 1187–93.
  7. Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA et al. A randomized, double-blind, placebocontrolled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. (Hoboken, N.j). 2015; 67 (10): 2702–12. DOI: 10.1002/art.39257.
  8. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee MJ, Rahbar MH, et al. The impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis. Arthritis Rheumat. 2013; 65 (10): 2645–54. DOI: 10.1002/art.38070.
  9. Callhoff J, Sieper J, Weiss A, Zink A, Listing J. Efficacy of TNF blockers in patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis: a meta-analysis. Ann. Rheum. Dis. 2015; (74): 1241–48.
  10. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P et al Antiinterleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebocontrolled trial. Lancet. 2013; 382 (9906): 1705–13.
  11. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P. et al/ Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015; (373): 2534–48.
  12. Helling B, König M, Dälken B, et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015; 93 (4): 396–405. DOI: 10.1038/icb.2014.102
  13. Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016; 8 (8): 889–906.
  14. König M, Rharbaoui F, Aigner S, Dälken B, Schüttrumpf J. Tregalizumab – A Monoclonal antibody to target regulatory T cells. Front Immunol. 2016; (7): 11. DOI: 10.3389/fimmu.2016.00011
  15. Duarte J, Agua-Doce A, Oliveira V, Fonseca JE, Graca L. Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS One. 2010; 5 (5): e10558. DOI: 10.1371/journal.pone.0010558
  16. Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3- specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med. 2008: 14 (5): 528–35. DOI: 10.1038/nm1749.
  17. Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol. 2006; (6): 883–94.
  18. Lavasani S, Dzhambazov B, Andersson M. Monoclonal antibody against T-cell receptor αβ induces self-tolerance in chronic experimental autoimmune encephalomyelitis. Scandinavian Journal of Immunology. 2007; (65): 39–47. DOI: 10.1111/j.1365- 3083.2006.01866.x
  19. Qi Q, Liu Y, Cheng Y, Glanville J, Zhang D, Lee Ji-Y, Olshen RA, Weyand C, Boyd SD, and Goronzy JJ. Diversity and clonal selection in the human T-cell repertoire. PNAS. 2014; 111 (36): 13139–44. https://DOI.org/10.1073/pnas.1409155111
  20. Faham M, Carlton V, Moorhead M, Zheng J, Klinger M, Pepin F. et al. Discovery of T cell receptor β motifs specific to HLA–B27– Positive ankylosing spondylitis by deep Repertoire sequence analysis. Arthritis & Rheumatology. 2017; (69): 774–84. DOI: 10.1002/art.40028
  21. Komech E, Pogorelyy M, Egorov E, Britanova O, Rebrikov D, Bochkova A, et al. CD8+ T cells with characteristic T cell receptor beta motif are detected in blood and expanded in synovial fluid of ankylosing spondylitis patients. Rheumatology. 2018, 579 (6): 1097–104. https://DOI.org/10.1093/rheumatology/kex517
  22. Stewart R, Thom G, Levens M, Güler-Gane G, Holgate R, Rudd PM et al. A variant human IgG1-Fc mediates improved ADCC. Protein Engineering, Design and Selection. 2011; 24 (9): 671–8. https://DOI.org/10.1093/protein/gzr015
  23. Britanova OV, Shugay M, Merzlyak EM, Staroverov DB, Putintseva EV, Turchaninova MA et al. Dynamics of Individual T Cell Repertoires: From Cord Blood to Centenarians. J. Immunol. 2016; 15, 196 (12): 5005–13. DOI: 10.4049/jimmunol.1600005.
  24. Shugay M, Bagaev DV, Turchaninova MA, Bolotin DA, Britanova OV, Putintseva EV. et al. VDJtools: Unifying Postanalysis of T Cell Receptor Repertoires. PLoS computational biology. 2015; (11): e1004503.
  25. Egorov ES, Kasatskaya SA, Zubov VN, Izraelson M, Nakonechnaya TO, Staroverov DB et al. The changing landscape of naive T cell receptor repertoire with human aging. Front Immunol. 2018; (9): 1618. https://DOI.org/10.3389/fimmu.2018.01618
  26. Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology. 1968; 14 (2): 181–96.
  27. Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, et al. A novel method for evaluating antibodydependent cell-mediated cytotoxicity by flow cytometry using cryopreserved human peripheral blood mononuclear cells. Sci Rep. 2016; (6): 19772. DOI: 10.1038/srep19772
  28. Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch GS, Waldor MK, et al. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell. 1988; 54 (2): 263–73.
  29. Chiocchia G, Boissier M, Fournier, C. Therapy against murine collagen-induced arthritis with T cell receptor Vβ-specific antibodies. Eur J Immunol. 1991; (21): 2899–905. DOI:10.1002/ eji.1830211202
  30. Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009; 5 (5): 499–521.
  31. Bruno V, Battaglia G, Nicoletti F. The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurol Sci. 2011; 31 (Suppl 3): 283–288. DOI 10.1007/s10072- 010-0382-6